Immunocore Holdings plc (NASDAQ:IMCR) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Immunocore Holdings plc (NASDAQ:IMCR) have been assigned an average recommendation of “Moderate Buy” from the thirteen analysts that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $65.64.

A number of equities analysts have issued reports on IMCR shares. Morgan Stanley restated an “equal weight” rating and issued a $35.00 price objective (down previously from $74.00) on shares of Immunocore in a research report on Friday, December 13th. Needham & Company LLC cut their target price on Immunocore from $78.00 to $71.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Immunocore in a research report on Thursday, October 24th. Guggenheim lowered Immunocore from a “buy” rating to a “neutral” rating in a research report on Monday, October 7th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a report on Monday, September 9th.

Institutional Investors Weigh In On Immunocore

Hedge funds have recently bought and sold shares of the business. Exchange Traded Concepts LLC lifted its holdings in shares of Immunocore by 40.4% during the third quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock valued at $158,000 after purchasing an additional 1,461 shares during the last quarter. Connective Portfolio Management LLC bought a new position in Immunocore during the 3rd quarter valued at approximately $218,000. China Universal Asset Management Co. Ltd. raised its stake in Immunocore by 69.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock valued at $231,000 after buying an additional 3,053 shares during the last quarter. XTX Topco Ltd bought a new stake in Immunocore in the second quarter worth $303,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of Immunocore in the third quarter worth $406,000. Institutional investors own 84.50% of the company’s stock.

Immunocore Trading Up 0.2 %

Shares of IMCR stock opened at $29.40 on Wednesday. The business has a 50-day moving average of $32.22 and a 200 day moving average of $34.95. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. Immunocore has a 1-year low of $28.17 and a 1-year high of $76.98. The stock has a market capitalization of $1.47 billion, a PE ratio of -30.95 and a beta of 0.73.

Immunocore (NASDAQ:IMCR) last issued its earnings results on Wednesday, November 6th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.50. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The firm had revenue of $80.25 million for the quarter, compared to analysts’ expectations of $78.94 million. During the same quarter last year, the business earned ($0.59) earnings per share. The business’s revenue was up 23.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Immunocore will post -0.94 earnings per share for the current year.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.